Should We Be Doing Cytoreductive Surgery with HIPEC for Signet Ring Cell Appendiceal Adenocarcinoma? A Study from the US HIPEC Collaborative.
Nick C LevinskyMackenzie C MorrisKoffi WimaJeffrey J SussmanSyed A AhmadJordan M CloydCharles KimbroughKeith FournierAndrew LeeSean DineenSophie DessureaultJula VeerapongJoel M BaumgartnerCallisia ClarkeMohammad Y ZaidiCharles A StaleyShishir K MaithelJennifer LeitingTravis GrotzLaura LambertRyan J HendrixSean Ronnekleiv-KellyCourtney PokrzywaMustafa RaoofOliver S EngFabian M JohnstonJonathan GreerSameer H PatelPublished in: Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (2019)
While signet cells are a negative prognostic feature, they should not be a contraindication to CRS-HIPEC in patients with well-moderately differentiated tumors with negative lymph nodes, where complete cytoreduction can be achieved.
Keyphrases
- lymph node
- induced apoptosis
- minimally invasive
- cell cycle arrest
- single cell
- low grade
- squamous cell carcinoma
- coronary artery bypass
- machine learning
- cell therapy
- cell death
- endoplasmic reticulum stress
- stem cells
- signaling pathway
- surgical site infection
- early stage
- mesenchymal stem cells
- metastatic renal cell carcinoma
- neural network